Ceneviva G, Paschall J A, Maffei F, Carcillo J A
Department of Anesthesiology and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Pediatrics. 1998 Aug;102(2):e19. doi: 10.1542/peds.102.2.e19.
Assess outcome in children treated with inotrope, vasopressor, and/or vasodilator therapy for reversal of fluid-refractory and persistent septic shock.
Survey; case series.
Three pediatric hospitals.
Fifty consecutive patients with fluid-refractory septic shock with a pulmonary artery catheter within 6 hours of resuscitation.
Patients were categorized according to hemodynamic state and use of inotrope, vasopressor, and/or vasodilator therapy to maintain cardiac index (CI) >3.3 L/min/m2 and systemic vascular resistance >800 dyne-sec/cm/m to reverse shock.
Hemodynamic state, response to class of cardiovascular therapy, and mortality.
After fluid resuscitation, 58% of the children had a low CI and responded to inotropic therapy with or without a vasodilator (group I), 20% had a high CI and low systemic vascular resistance and responded to vasopressor therapy alone (group II), and 22% had both vascular and cardiac dysfunction and responded to combined vasopressor and inotropic therapy (group III). Shock persisted in 36% of the children. Of the children in group I, 50% needed the addition of a vasodilator, and in group II, 50% of children needed the addition of an inotrope for evolving myocardial dysfunction. Four children showed a complete change in hemodynamic state and responded to a switch from inotrope to vasopressor therapy or vice versa. The overall 28-day survival rate was 80% (group I, 72%; group II, 90%; group III, 91%).
Unlike adults, children with fluid-refractory shock are frequently hypodynamic and respond to inotrope and vasodilator therapy. Because hemodynamic states are heterogeneous and change with time, an incorrect cardiovascular therapeutic regimen should be suspected in any child with persistent shock. Outcome can be improved compared with historical literature.
评估接受正性肌力药、血管升压药和/或血管扩张剂治疗以逆转液体难治性和持续性感染性休克的儿童的治疗结果。
调查;病例系列。
三家儿科医院。
50例在复苏6小时内患有液体难治性感染性休克且置入肺动脉导管的连续患者。
根据血流动力学状态以及使用正性肌力药、血管升压药和/或血管扩张剂治疗以维持心脏指数(CI)>3.3L/分钟/平方米和全身血管阻力>800达因·秒/厘米/米来逆转休克对患者进行分类。
血流动力学状态、对心血管治疗类别的反应及死亡率。
液体复苏后,58%的儿童CI较低,对使用或未使用血管扩张剂的正性肌力治疗有反应(I组),20%的儿童CI较高且全身血管阻力较低,仅对血管升压药治疗有反应(II组),22%的儿童存在血管和心脏功能障碍,对血管升压药和正性肌力联合治疗有反应(III组)。36%的儿童休克持续存在。I组中,50%的儿童需要加用血管扩张剂,II组中,50%的儿童因出现心肌功能障碍需要加用正性肌力药。4名儿童血流动力学状态发生完全改变,对从正性肌力药治疗转换为血管升压药治疗或反之有反应。总体28天生存率为80%(I组为72%;II组为90%;III组为91%)。
与成人不同,液体难治性休克的儿童常为低动力状态,对正性肌力药和血管扩张剂治疗有反应。由于血流动力学状态具有异质性且随时间变化,任何持续休克的儿童都应怀疑心血管治疗方案不正确。与历史文献相比,治疗结果可得到改善。